41 results about "Mouse Hippocampus" patented technology

The invention provides a circular RNA circ0004801 and an application of the circular RNA circ0004801 in treatment of an Alzheimer's disease. The nucleotide sequence of the circular RNA circ0004801 is as shown in SEQ ID NO: 1 (Sequence Identity Number 1). The expression of the circular RNA circ0004801 in the hippocampal tissue of the AD mouse is obviously up-regulated, and the circular RNA circ0004801 is used as a'sponge 'of miR-7688-5p and plays a role by adjusting the TTBK1 expression and tau phosphorylation level. By knocking down the circular RNA circ0004801, the spatial learning and memory of a 3 * Tg mouse can be obviously improved, and the tau protein phosphorylation level of a hippocampus region and the NFTs density of a hippocampus DG region can be obviously reduced. Therefore, the circular RNA circ0004801 and the miR-7688-5p can be used as new targets for treating the AD (Alzheimer's disease). According to the invention, it is found for the first time that circular RNA circ0004801 regulates TTBK1 through a ceRNA mechanism, so that excessive phosphorylation of tau is driven, and a new molecular target is provided for AD early intervention treatment based on circRNA and miRNA.

The invention provides a method for establishing a mouse postoperative delirium model under a simulated high altitude urgent entry environment, and relates to the technical field of animal model establishment. According to the method for establishing the model for simulating postoperative delirium of the mouse in the sudden entering plateau environment, a control group (group C), a plateau group (group H), a POD model group (group P) and a plateau POD model group (group HP) are included, behavior changes of the mouse are evaluated through a Y maze experiment, then the mouse is killed, brain tissue is taken, and the mouse is subjected to postoperation delirium simulation in the sudden entering plateau environment. The mouse hippocampus tissue structure damage change is observed through morphological methods such as Nissl staining and a transmission electron microscope, meanwhile, blood is taken through mouse eye sockets, the concentration of inflammatory related indexes IL-6 and TNF-alpha in serum is measured through an ELISA method, and the stability and repeatability of model establishment are known. The plateau postoperative delirium mouse model prepared by the invention can generate obvious damage to brain tissues and neurological functions, and is high in operability and good in repeatability.

The invention discloses a compound with remarkable 5-hydroxytryptamine (5-HT) reuptake inhibition activity, a preparation method of the compound and application of the compound in preparation of anti-depression drugs. And the compound is a compound Oreonudine C. The invention further discloses a preparation method of the compound. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, extracting with chloroform, and performing silica gel column chromatography, C18 ODS column chromatography and preparative high performance liquid chromatography on the chloroform extraction part to obtain the Oreonudine C. The invention further discloses a preparation method of the Oreonudine C. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, and obtaining the Oreonudine C. In-vitro experiments show that the compound Oreonudine C remarkably inhibits reabsorption of 5-HT (the inhibition rate is 60.4%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine C is superior to that of a positive control drug amitriptyline (the inhibition rate is 53.6%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.

The application discloses an application of Campanula medium in treatment of perimenopausal depression, and a method is as follows: Campanula medium is added into 10 times of distilled water in weight, decocted for 1 h and filtered, residues are added with 8 times of distilled water, and then decocted for 1 h and filtered, and filtrates are combined, and concentrated into 1 g / mL of medicinal liquid according to medicinal material, so that Campanula medium medicinal liquid is obtained. According to the experimental result, Campanula medium can improve the depression and anxiety behavior of PMD model mice. Campanula medium can improve the hippocampus tissue morphology and structure of the PMD model mice, increase the neuron Nissl body abundance of the hippocampus, promote the ER-BDNF-TrkB path, improve the monoamine neurotransmitter level, correct the HPA axis hyperactivity, and thus improve the depression behavior.

The invention relates to the technical field of learning and memory ability evaluation, and provides a mouse hippocampus learning and memory ability comprehensive evaluation method and system based on a Morris water maze, the method is different from a traditional method for evaluating learning and memory only through an incubation period, a mouse behavior character stability and swimming skill dual evaluation mechanism is innovatively introduced, and the method is suitable for comprehensive evaluation of learning and memory ability of a mouse hippocampus. And in combination with a training adaptation period, behavior path analysis and weighted scoring of multi-dimensional behavior indexes, precise quantification of the hippocampus dependency space learning and memory ability is realized. The experimental indexes comprise swimming speed, path length, target quadrant residence time and incubation period, and performing standardized calculation after weight assignment to generate a memory ability evaluation score. According to the invention, the scientificity, stability and experimental repeatability of an evaluation result are improved, and the method is suitable for mouse cognitive function evaluation under various research situations such as drug intervention, neurodegenerative disease models and the like.

This invention provides the application of *Ackermania guangxiensis* extracellular polysaccharide in the preparation of anti-aging products, belonging to the technical field of microbial polysaccharide pharmaceutical applications. This invention extracts extracellular polysaccharides from *Ackermania guangxiensis* using the TCA precipitation method. Animal experiments show that *Ackermania guangxiensis* extracellular polysaccharide can effectively reduce MDA content in aging model mice while increasing SOD activity; it improves the thinning of the dermal layer, reduction and loosening of collagen fibers, and other signs of aging in model mice, and increases the hydroxyproline content in the skin; furthermore, it can activate the expression of BDNF and TrKB genes in the mouse hippocampus and alleviate problems such as slow movement, cognitive impairment, and memory decline in model mice. Therefore, the *Ackermania guangxiensis* extracellular polysaccharide provided by this invention has good anti-aging and antioxidant activity and can be used to prepare various anti-aging products.

The application discloses application of TESC as an Alzheimer's disease prevention and treatment target and relates to the field of biological medicines. A TESC overexpression (TESC-OE) hippocampal neuron cell line is constructed through lentivirus transfection, and the result shows that TESC-OE has the ability to resist A beta-induced neuron apoptosis and synapse damage. A TESC overexpression model in the hippocampus of a mouse is constructed through stereotactic injection of an adeno-associated virus, and the result shows that the hippocampal gray matter volume in the brain of the TESC-OE mouse is significantly larger than that of a wild type mouse. A beta stereotactic modeling is performed on the basis of TESC overexpression in the hippocampus, and the result shows that the TESC-OE mouse can significantly resist A beta-induced hippocampal atrophy, learning and memory dysfunction and impaired synaptic plasticity. Immunoblotting analysis reveals the molecular mechanism that TESC can increase the expression of anti-apoptotic genes in the hippocampus and reduce the expression of pro-apoptotic genes to exert a neuroprotective effect.

The invention discloses a method for synergistically treating Alzheimer's disease through gene-modified human interdental stem cells, and belongs to the field of drug therapy. According to the method, healthy adult dental pulp mesenchymal stem cells (hDPSCs) are extracted, BDNF and NRF2 genes are introduced through lentiviral vectors, the BDNF and NRF2 genes have neurotrophic, antioxidant and anti-inflammatory capacities, and then the hDPSCs are combined with curcumin nanoparticles and injected to the hippocampus of an AD mouse through stereotactic injection. The BDNF can promote nerve regeneration, the NRF2 can improve oxidative stress and inflammation environment, and the curcumin nanoparticles regulate A beta metabolism and activate a BDNF signal channel. Experiments show that the combined therapy can significantly enhance hippocampal neurogenesis of AD mice and improve expression of neuron markers, and it is proved through Morse water maze tests that the combined therapy can improve the spatial learning and memory ability of the mice. The method breaks through the limitation of traditional single-target treatment, multi-dimensional pathological intervention is achieved, the stem cells are rich in source and high in safety, and a new strategy is provided for treatment of the Alzheimer's disease.

The invention discloses calf animal coccus PD13 for improving Alzheimer's disease and application of the calf animal coccus PD13, and relates to the technical field of biology. Experiments prove that in an Alzheimer's disease model mouse induced by injecting A beta oligomer into the brain, the Azococcus calvus PD13 can improve spatial learning and memory disorder and autonomous exploration ability of the AD model mouse and relieve damage to neurons in a hippocampal region of the Alzheimer's disease model mouse, so that the effect of protecting the neurons is achieved, and the Azococcus calvus PD13 can be used for preparing a medicine for treating the Alzheimer's disease. According to the present invention, with the application of the animal coccus calves, the content of glutathione in mouse serum and the enzyme activity of superoxide dismutase are increased, and the content of malondialdehyde is reduced, such that the animal coccus calves provides good prevention and treatment effects on the Alzheimer's disease, and the new approach is provided for developing the Alzheimer's disease-related drugs.

The invention belongs to the technical field of medicines, and particularly relates to preparation of CD73 positive NK cells of umbilical cord blood from different starting sources and application of the CD73 positive NK cells to treatment of Alzheimer's disease. The CD73 + NK cells differentiated from different initial cell types (CD34 positive cells, CD3 negative / CD56 positive cells and CD56 negative cells) of umbilical cord blood are studied, it is found that all the initial cell types of umbilical cord blood sources can be differentiated into the CD73 + NK cells, 34 +-73-NK cells show a higher growth rate, 56-73-NK cells show higher cytotoxicity, and the CD73 + NK cells can be differentiated into the CD73 + NK cells. And the overall effect of the 56-73-NK cell is superior to that of the 34 < + >-73-NK cell. Further research shows that the CD73 + NK can inhibit activation of STZ injection mouse hippocampal microglia and astroglia, so that the neuroinflammation of the hippocampal is reduced, and a new solution is expected to be provided for treatment of AD.

The invention relates to the technical field of fluorescent molecular materials for biological imaging, in particular to an N-phenylpiperazine fluorescent probe molecule as well as a preparation method and application thereof. The probe molecule is a fluorescent ligand receptor combined type fluorescent sensor, takes N-(2-methoxyphenyl) piperazine as a targeting group and 4-dimethylamino-1, 8-naphthalimide as a fluorescent reporter group, has specific recognition capability on a dopamine D3 receptor, and is excellent in fluorescence performance, low in cytotoxicity, fast in cell uptake (10s) and remarkable in fluorescence enhancement; the method can be used for cell imaging of mouse hippocampal nerve HT-22 cells, achieves the purpose of visualization, and has potential development value and good application prospects. The fluorescent probe is short in synthesis route, simple and easy to operate and suitable for industrial popularization and application.

The invention discloses a pharmaceutical composition for promoting neuron neogenesis and a method for promoting neuron neogenesis by using a gastrodia elata extract or an adenosine analogue. The gastrodia elata extract comprises gastrodin, gastrodigenin, a parishins compound, N6-(4-hydroxybenzyl) adenosine (T1-11) and 4-hydroxybenzaldehyde (4-hydroxybenzaldehyde). The invention also discloses a method for promoting neuron neogenesis by using the gastrodia elata extract or the adenosine analogue. The gastrodia elata extract provided by the invention has aging-retarding activity on nerve cells and can induce mouse hippocampal neuronal neogenesis.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

The present application mainly relates to the separation and identification and application of active ingredients in traditional Chinese medicine, and specifically discloses a separation and purification of a steroidal saponin compound in Allii Macrostemonis Bulbus. According to the physical and chemical properties and high-resolution electrospray mass spectrometry (HR-ESI-MS), one-dimensional / two-dimensional nuclear magnetic resonance spectroscopy (1D- / 2D-NMR) and other spectral technologies, the structure of the compound is identified, the structure is analyzed and the molecular formula is determined, and finally named as Allii Macrostemonis Bulbus saponin U. The pharmacological activity of Allii Macrostemonis Bulbus saponin U is studied through in vitro cell experiments, and it is found that Allii Macrostemonis Bulbus saponin U significantly improves the cell viability of mouse hippocampal neurons after glutamate treatment, has good neuroprotective activity, and can be used for the preparation and application of anti-nerve injury drugs.

The invention belongs to the field of new application of medicines, and particularly relates to application of N-phenylpiperazine derivatives in preparation of medicines for treating neuroinflammation. It is found for the first time that the N-phenylpiperazine derivative AD-X can improve the neuroinflammation of mice by activating microglia in hippocampus and prefrontal cortex of the mice, and has a certain function of treating the neuroinflammation. The invention provides a novel lead compound for screening medicines for treating neuroinflammation.

The invention relates to the technical field of bioactive peptides, in particular to application of sipunculus nudus polypeptide in preparation of a neuroprotective drug. According to the specific technical scheme, firstly, sipunculus nudus oligopeptide is obtained through enzymolysis and an ultrafiltration membrane separation technology, the sipunculus nudus oligopeptide is separated and purified through sephadex chromatography, and on the basis of a high-glucose-induced mouse hippocampal neuron HT22 cell damage model, the collected components are separated and purified to obtain the sipunculus nudus oligopeptide. The neuroprotective effects of the sipunculus nudus oligopeptide and the separated components thereof are deeply discussed, and then the components in the sipunculus nudus oligopeptide are further separated and purified and subjected to mass spectrum peptide sequence identification by adopting reverse-phase high performance liquid chromatography. Experimental results show that the three components separated from the sipunculus nudus oligopeptide through sephadex chromatography can effectively improve the cell activity of HT22 cells after high glucose damage, and accumulation of ROS (reactive oxygen species) in the cells and occurrence of apoptosis are remarkably reduced.

The invention relates to casein peptide hydrolysate and application thereof in preparation of drugs for preventing or treating nerve aging, and belongs to the technical field of biological medicines. The casein hydrolysate is obtained by fermenting a casein solution with the probiotic bifidobacterium longum BNCC 185354, and the obtained casein hydrolysate has superoxide anion free radical scavenging capacity, can prolong the telomere length of the hippocampus of a subacute aging model mouse and relieve DNA oxidative damage of the hippocampus of the mouse. The brand-new casein peptide with both brain-accessible activity and biological activity is further screened from casein hydrolysate, free radicals can be removed, nerve cell inflammation can be eliminated, and therefore nerve aging is delayed. The casein peptide and the casein hydrolysate provided by the invention can be applied to preparation of drugs for preventing and / or treating nerve aging, and have good application prospects.

The invention discloses Weissella sinus PD13 for improving Alzheimer's disease and application of the Weissella sinus PD13, and relates to the technical field of biological medicine. Experiments prove that Weissella cibaria PD13 can improve spatial learning and memory impairment and autonomous exploration ability of AD model mice in Alzheimer's disease model mice induced by brain injection of A beta oligomer, and alleviate damage of neurons in hippocampal regions of the Alzheimer's disease model mice, so that the effect of protecting neurons is achieved, and the Weissella cibaria PD13 can be used for preparing drugs for treating Alzheimer's disease. According to the present invention, the Weissella cibaricola can effectively prevent and treat the Alzheimer's disease, increase the glutathione content and the superoxide dismutase enzyme activity of the mouse serum, and reduce the malondialdehyde content, such that the Weissella cibaricola has good prevention and treatment effects on the Alzheimer's disease, and the new approach is provided for developing the Alzheimer's disease-related drugs.

The invention belongs to the technical field of chemistry, and particularly relates to an artificial synthesis method and application of a compound theanine diglucoside TFG. Theanine-fructosyl-glucose (TFG) is a Maillard reaction product, has obvious antioxidant activity, and is not systematically studied at present, so that the antioxidant activity of the theanine-fructosyl-glucose (TFG) can be obviously improved, and the antioxidant activity of the theanine-fructosyl-glucose (TFG) can be obviously improved. The invention provides an efficient artificial synthesis method of the compound TFG, the synthesis cost is reduced, a material basis is provided for subsequent research, and the method has the characteristics of economy, high efficiency, simplicity in operation, safety and the like, and is suitable for industrial production. Subsequently, activity screening of HT22 mouse hippocampal neuronal cells and HUVEC human vascular endothelial cells in vitro proves that the compound TFG can remarkably relieve cell oxidative damage induced by hydrogen peroxide (H2O2). Based on the synergistic protection effect of the TFG on neurons and vascular endothelial systems, the TFG is suitable for developing antioxidant drugs for treating Alzheimer's disease.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

The application discloses a target strategy and a drug intervention method for improving Primrose syndrome, and belongs to the technical field of biological medicine. The experiment proves that Momordin Ic can significantly improve the SUMO level of ZBTB20 in vitro cells or Primrose syndrome (PS) mice, can effectively improve the defects of reduced neuron dendritic branching in the hippocampal CA1 region of the PS mice in pathology, can enhance the complexity, and can improve the cognitive and emotional disorders such as memory impairment and anxiety-like behavior of the PS mice to different degrees in behavior. The application discloses that Momordin Ic can improve the PS-related neuropathological changes and behavioral cognitive defects by targeting the SENP1-ZBTB20-SUMO pathway, and provides a new candidate molecule and a clear action target for developing potential therapeutic drugs for Primrose syndrome.

The invention relates to the technical field of biology, and particularly discloses a polypeptide composition as well as a preparation method and application thereof. The polypeptide composition comprises American ginseng peptide, rhizoma polygonati peptide and ginkgo fruit peptide. The mass ratio of the American ginseng peptide to the rhizoma polygonati peptide to the ginkgo nut peptide is (20-100): (5-15): (20-150). According to the polypeptide composition disclosed by the invention, the specific raw materials are matched, so that the sleep latency period of an insomnia mouse is effectively shortened, the sleep maintenance time of the mouse is prolonged, the content of 5-HT in hippocampal tissues of the mouse is increased, and the effect of improving sleep is achieved. The raw materials used in the polypeptide composition are safe, and the polypeptide composition can effectively assist sleep and improve insomnia for a long time and has a good application prospect.

The invention discloses an application of polypeptide in preparation of antidepressant drugs, and belongs to the field of biological medicine, the polypeptide is neuropeptide PEN or a functional fragment and a derivative thereof, and the PEN is one of a plurality of derivative peptides formed by cutting a protein precursor proSAAS existing in a central nervous system of a mammal through proprotein convertase. Research finds that PEN as an endogenous polypeptide can significantly shorten the immobility time of a mouse in a tail suspension experiment and a forced swimming experiment and improve the depression-like behavior of the mouse, shows an obvious anti-depression effect, and has no obvious influence on the movement function of the mouse. A further research result shows that the anti-depression mechanism of PEN is related to inhibition of NMDAR2B / CaMKII signals of a mouse hippocampus and increase of ERK1 / 2 protein activity of the hippocampus. The invention discovers potential application of PEN in preparation of antidepressant drugs for the first time, and provides a new target and theoretical basis for development of novel, safe and effective antidepressant drugs.

The present invention relates to a composition and a method of utilizing Gastrodia elata extract or an adenosine analog to promote neurogenesis, wherein the G. elata extract includes gastrodin, gastrodigenin, parishins, N6-(4-hydroxybenzyl) adenosine (T1-11) and 4-hydroxybenzaldehyde. The G. elata extract of the present invention exhibits anti-aging activity on nerve cells and can induce neurogenesis in mouse hippocampus.

The invention discloses a tussilago farfara extract and application of the tussilago farfara extract in mood regulation and depression treatment. The tussilago farfara extract is prepared, the activation effect of the tussilago farfara extract on a neurotransmitter receptor is verified through a cell experiment, and the relieving effect of the tussilago farfara extract on depression-like symptoms of mice is verified through an animal experiment. The flos farfarae alcohol extract can improve the depression behavior of a mouse by activating a neurotransmitter receptor, and remarkably improve the content of 5-HT and DA in hippocampus of the depression mouse and the gene expression level of a 5-HT1A receptor and a D2 receptor in a prefrontal lobe. The tussilago farfara extract can be applied to medicines for treating neurotransmitter or neurotransmitter receptor mediated diseases or symptoms, and health care products, foods, cosmetics or daily necessities for regulating emotion.

The application discloses application of methyl palmitate in preparation of a medicine for treating and / or preventing senility and related cognitive impairment, and belongs to the technical field of biological medicine. The application proves by a cell experiment that methyl palmitate can significantly inhibit D-galactose-induced SH-SY5Y cell senility, and effectively reduce the expression level of senility-related proteins P53 and P16. The application proves by a behavior experiment that methyl palmitate can significantly improve the cognitive index of a senility model mouse, shorten an escape latency, and effectively improve learning ability reduction, spatial memory decline and cognitive function impairment caused by senility. In addition, methyl palmitate can significantly enhance the long-term potentiation effect of the hippocampal CA1 region of the senility model mouse, and reverse senility-related synaptic transmission damage. The application discloses the application of methyl palmitate in resisting neural senility and improving senility-related cognitive impairment, and provides a new candidate molecule for preparing a medicine for treating neurodegenerative diseases.

This invention discloses a 3-hydroxypyridinone derivative, its preparation method, and its applications. This 3-hydroxypyridinone derivative, through structural modification of the 3-hydroxypyridinone core, significantly enhances its anti-ferroptosis activity against hippocampal neurons in HT-22 mice. In vitro experiments show that its inhibitory effect on ferroptosis is more than twice that of the positive control deferoxone. Furthermore, the 3-hydroxypyridinone derivative can also chelate Fe... 3+ To alleviate iron-mediated Aβ 1‑42 Protein aggregation and its cytotoxicity. This invention also provides synthetic routes, purification methods, and in vitro activity evaluation systems for 3-hydroxypyridinone derivatives, offering structural optimization strategies and candidate compounds for the development of drugs targeting iron metabolism disorders.

The application provides a circular RNA circ_0004801 and application thereof in Alzheimer's disease treatment; a nucleotide sequence of the circular RNA circ_0004801 is shown as SEQ ID NO:1. Expression of the circular RNA circ_0004801 in hippocampus tissue of AD mice is significantly up-regulated, the circular RNA circ_0004801 acts as a "sponge" of miR-7688-5p, and plays a role by regulating TTBK1 expression and tau phosphorylation level. Knocking down the circular RNA circ_0004801 can obviously improve spatial learning and memory of 3xTg mice, significantly reduce tau protein phosphorylation level in hippocampus and NFTs density in hippocampus DG region. Therefore, the circular RNA circ_0004801 and miR-7688-5p can be used as a new target for treating AD. The application first finds that the circular RNA circ_0004801 regulates TTBK1 through a ceRNA mechanism, thereby driving tau hyperphosphorylation, and provides a new molecular target for early intervention treatment of AD based on circRNA and miRNA.

The invention provides a high-strength photo-thermal conversion microsphere as well as a preparation method and application thereof, and relates to the technical field of biomedical optical materials. The high-strength photothermal conversion PCM / SiO2 microsphere provided by the invention is a micron-sized functional material with optical characteristics of photonic crystals and high-efficiency heat conduction capability, can realize optical localization and slow photon effect, enhances photothermal conversion, and can be used as a photothermal conversion agent in near-infrared light treatment of POCD mice to remarkably improve brain temperature in a hippocampus DG region of the mice, so that the high-strength photothermal conversion PCM / SiO2 microsphere can be used for treating the POCD mice. The traditional Chinese medicine composition has a remarkable improvement effect on cognitive behaviors of POCD mice. The PCM / SiO2 microspheres prepared by the method disclosed by the invention have a wide application prospect in a photo-thermal treatment method.

This invention belongs to the field of medical technology, specifically relating to the preparation of CD73-positive NK cells from umbilical cord blood of different origins and their application in the treatment of Alzheimer's disease. This invention studies CD73-positive NK cells differentiated from different cell types originating from umbilical cord blood (CD34-positive cells, CD3-negative / CD56-positive cells, and CD56-negative cells). + NK cells were found to differentiate into CD73 from all initial cell types derived from umbilical cord blood. + NK cells, and 34 + -73-NK cells showed a higher growth rate, 56 － -73-NK cells exhibited stronger cytotoxicity, and 56 － -73-NK cells showed better overall efficacy than 34- + -73-NK cells. Further research indicates that CD73 + NK cells can inhibit the activation of microglia and astrocytes in the hippocampus of STZ-injected mice, thereby reducing neuroinflammation in the hippocampus and potentially providing a new solution for the treatment of AD.